Created byAdam Bent
Published 10/30/26 AT 5:27 PM EDT
For those battling cancer, breakthroughs mean a possible new lease on life. Under Dr. Gabi Hanna’s leadership, scientist-led Lamassu Biotech aims to revive the body’s own tumor suppressor gene to bring hope and healing to patients battling rare cancers, and why he says speed is an ethical obligation.
Cancer research has advanced significantly over the past decade, yet translating discoveries into effective treatments remains one of healthcare’s hardest problems. Precision oncology is opening new ways to target cancer at the molecular level, but patients with rare, aggressive, and hard-to-treat tumors still face limited options, and many are still treated with drugs developed more than 60 years ago. For Hanna, a physician-entrepreneur and co-founder of the clinical-stage biotechnology company, closing that gap requires more than scientific innovation. It requires a different approach to how traditional biotech companies are founded, developed, and connected to the wider medical community.
CLICK HERE to read the full story from the International Business Times.
